Dasotraline FDA Approval Status
Last updated by Judith Stewart, BPharm on May 21, 2020.
Dasotraline is a dual dopamine and norepinephrine reuptake inhibitor (DNRI) in development for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder.On May 13, 2020, Sunovion announced the withdrawal of the New Drug Applications (NDAs) for dasotraline, citing that further clinical studies would be needed to support regulatory approval.
Development timeline for dasotraline
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.